Citadel Advisors
XRTX

Citadel Advisors’s XORTX Therapeutics XRTX Stock Holding History

Citadel Advisors’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,265
Closed -$69.9K – 14279
2025
Q3 		$69.9K Buy
17,265
+9,571
+124% +$40.1K ﹤0.01% 12037
2025
Q2 		$35.8K Buy
+7,694
New +$36.3K ﹤0.01% 11920
2024
Q3 		– Sell
-2,467
Closed -$23.3K – 15393
2024
Q2 		$23.3K Buy
+2,467
New +$33K ﹤0.01% 12502
2023
Q3 		– Sell
-69
Closed -$18.3K – 15242
2023
Q2 		$18.3K Buy
+69
New +$19K ﹤0.01% 12811
2023
Q1 		– Sell
-44
Closed -$14.7K – 15617
2022
Q4 		$14.7K Buy
+44
New +$15.6K ﹤0.01% 13375

Other funds holding XRTX

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

Citadel Advisors's XRTX Position: Q4 2025 in Review

Citadel Advisors sold out of XORTX Therapeutics (XRTX) in Q4 2025, closing a stake of 17,265 shares — an estimated $69.9K sold.

Citadel Advisors first reported a position in XRTX in Q4 2022 and held it in 5 quarters. The position peaked at $69.9K in Q3 2025. 6 funds tracked by Wall St. Rank hold XRTX as of Q4 2025.

  • Citadel Advisors reported no remaining XORTX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 17,265 XORTX Therapeutics shares in Q4 2025, an estimated $69.9K.
  • Citadel Advisors first reported a position in XORTX Therapeutics in Q4 2022 and held it in 5 quarters.
  • Citadel Advisors's XORTX Therapeutics position peaked at $69.9K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.